Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
British Journal of Cancer
|
December 8, 2005
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
K Yao, J A Gietema, S Shida, et al.
Investigational New Drugs
|
January 1, 1995
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer
N B Haas, R J Schilder, S Nash, et al.
Cancer Research
|
March 1, 1994
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
N B Haas, F P LaCreta, J Walczak, et al.
Investigational New Drugs
|
January 28, 2014
Phase II trial of vorinostat in advanced melanoma
N B Haas, I Quirt, S Hotte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A R Hansen, C Massard, P A Ott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 27, 2016
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial
S M Keefe, J Hoffman-Censits, R B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M H Voss, A Hussain, N Vogelzang, et al.
Kidney Cancer (Clifton, Va.)
|
October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward
L C Harshman, C G Drake, N B Haas, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
British Journal of Cancer
|
December 8, 2005
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
K Yao, J A Gietema, S Shida, et al.
Investigational New Drugs
|
January 1, 1995
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer
N B Haas, R J Schilder, S Nash, et al.
Cancer Research
|
March 1, 1994
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
N B Haas, F P LaCreta, J Walczak, et al.
Investigational New Drugs
|
January 28, 2014
Phase II trial of vorinostat in advanced melanoma
N B Haas, I Quirt, S Hotte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
A R Hansen, C Massard, P A Ott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 27, 2016
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial
S M Keefe, J Hoffman-Censits, R B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M H Voss, A Hussain, N Vogelzang, et al.
Kidney Cancer (Clifton, Va.)
|
October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward
L C Harshman, C G Drake, N B Haas, et al.
Page
of 2